טוען...
Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists
OBJECTIVE: To explore the implications of direct-to-consumer pharmacogenomic testing for community pharmacy practice. SUMMARY: In October 2018, the U.S. Food and Drug Administration provided approval for direct-to-consumer genetic testing company, 23andMe® (Mountain View, CA), to return select pharm...
שמור ב:
| הוצא לאור ב: | J Am Pharm Assoc (2003) |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7229642/ https://ncbi.nlm.nih.gov/pubmed/31327749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.japh.2019.06.008 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|